Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV003476727 | SCV004200973 | uncertain significance | Polyps, multiple and recurrent inflammatory fibroid, gastrointestinal | 2023-05-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003638965 | SCV004452577 | uncertain significance | Gastrointestinal stromal tumor | 2023-04-06 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on PDGFRA protein function. This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change replaces methionine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 745 of the PDGFRA protein (p.Met745Ile). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |